Clinical trials: IGA Glomerulonephritis
Finerenone, IgA Nephropathy
Study of the Clinical Efficacy and Safety of Finerenone for the Treatment of IGA Nephropathy
IgA nephropathy accounts for about 45 per cent of primary glomerular diseases in China and about 26 per cent of renal biopsies in patients with chronic failure.According to current guideline recommendations, there are limited…
- Conditions
- Finerenone, IgA Nephropathy, Proteinuria, Safety Issues
- Trial name
- NCT06460987
- Testing
- Finerenone, RAS inhibitor, Immune Suppressant
- Where
- China
- Volunteers
- 245 people
- Sponsor
- The Fourth Affiliated Hospital of Zhejiang University School of Medicine
Proteinuric Kidney Disease, Diabetic Nephropathy
Aldosterone Breakthrough During Diovan, Tekturna, and Combination Therapy in Patients With Proteinuric Kidney Disease
Primary Hypothesis: Aldosterone breakthrough will occur at a far lower frequency during renin inhibition (0-10% over 9 months), alone or in combination with an ARB, compared to conventional ARB therapy (35-45% over 9 months).
- Conditions
- Proteinuric Kidney Disease, Diabetic Nephropathy, Hypertensive Nephrosclerosis, IgA Nephropathy
- Trial name
- NCT01129557
- Testing
- Aliskiren, Valsartan
- Where
- United States
- Volunteers
- 46 people
- Sponsor
- Columbia University
Anti-neutrophil Cytoplasmic Antibody-associated Vasculitis
A Study in Healthy Volunteers to Evaluate the Drug-Drug Interaction Potential of CCX168 With Concomitant Medications
The primary objective of this study will be to evaluate the drug-drug interaction potential of CCX168 with concomitant medications, as either a perpetrator or a victim, following oral administration of CCX168 to healthy…
- Trial name
- NCT06004947
- Testing
- CCX168, Midazolam, Celecoxib
- Where
- United States
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Amgen
IgA Nephropathy (IgAN)
RESistance of IgA Nephropathy to Conventional and Newly-approved Therapies: an Observational, Real-life Study (RESIGAN)
IgA nephropathy (IgAN) is the most common primary glomerulonephritis worldwide, characterized by glomerular mesangial IgA deposits, often with IgG and C3. Despite its prevalence, the pathophysiology of IgAN is poorly understood.
- Trial name
- RESIGAN (NCT06926244)
- Where
- France
- Volunteers
- 800 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
IgA Nephropathy
Study of ARO-CFB in Adult Healthy Volunteers
The purpose of AROCFB-1001 is to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of ARO-CFB Injection in adult healthy volunteers (HVs). HVs will receive either one or two doses of ARO-CFB or placebo.
- Trial name
- NCT06209177
- Testing
- ARO-CFB
- Where
- New Zealand
- Volunteers
- 49 people, healthy volunteers welcome
- Sponsor
- Arrowhead Pharmaceuticals
IgA Nephropathy (IgAN)
Avacopan in Crescentic Immunoglobulin A Nephropathy (IgAN)
The purpose of this study is to evaluate the efficacy and safety of Avacopan together with low-dose glucocorticoid in the treatment of patients with crescentic Imunoglobulin A Nephropathy (IgAN) and high risk of progression.
- Trial name
- NCT06676579
- Testing
- Avacopan, Prednisone, Methylprednisolone (drug)
- Where
- 2 sites in United States
- Volunteers
- 16 people
- Sponsor
- Mayo Clinic
IGA Nephropathy
A Study of Treatment Patterns and Real-World Outcomes in IgA Nephropathy Patients in the United States
The aim of this study was to characterize real-world treatment patterns, including therapy sequences, escalation, and duration, and treatment outcomes in IgA nephropathy (IgAN) patients in the United States (US).
- Trial name
- NCT07757048
- Where
- United States
- Volunteers
- 6,286 people
- Sponsor
- Novartis Pharmaceuticals
IgA Nephropathy (IgAN)
To Evaluate the Effect and Safety of Telitacicept and Standard Treatment for 6months in IgA Nephropathy
The purpose of this clinical study is to evaluate the efficacy and safety of that test group was administered with Telitacicept in patients with IgA nephropathy.
- Trial name
- NCT07098897
- Testing
- Telitacicept 160mg, Corticosteroid, ACE Inhibitor or Angiotensin receptor antagonist
- Where
- China
- Volunteers
- 150 people
- Sponsor
- The Affiliated Hospital of Xuzhou Medical University
Purpura, Schoenlein-Henoch
HSP-glomerulonephritis Trial: MP vs CyA
No curative treatment of severe HSP nephritis is known. Apart from corticosteroids, immunosuppressive drugs, such as azathioprine and cyclophosphamide, have been used to treat severe HSP nephritis.Limited patient series treated…
- Trial name
- NCT00425724
- Testing
- Methylprednisolone pulses plus prednisone versus Cyclosporine A
- Where
- Finland
- Volunteers
- 20 people
- Sponsor
- Oulu University Hospital
Immunoglobulin A (IgA) Nephropathy
Clinical Trial to Assess Efficacy and Safety of the Human Anti-CD38 Antibody Felzartamab (MOR202) in IgA Nephropathy
Randomized, placebo-controlled, multi-center, double-blind, proof of concept phase IIa trial and dose evaluation trial of felzartamab in IgAN
- Trial name
- IGNAZ (NCT05065970)
- Testing
- Felzartamab
- Where
- 59 sites in United States, Australia and 13 more
- Volunteers
- 54 people
- Sponsor
- HI-Bio, A Biogen Company
IgA Nephropathy
Study of Safety and Efficacy of LNP023 in Patients With Kidney Disease Caused by Inflammation
Efficacy and safety of LNP023 in IgAN patients
- Trial name
- NCT03373461
- Testing
- LNP023
- Where
- 56 sites in Argentina, Australia and 23 more
- Volunteers
- 112 people
- Sponsor
- Novartis Pharmaceuticals
IgA Nephropathy (IgAN), Renal and Urinary Disorders
A Rollover Study to Evaluate the Long-Term Safety and Efficacy of Atacicept
The purpose of this study is to collect long-term safety and tolerability data for atacicept in patients with IgAN that completed Vera trial investigating atacicept in IgAN population.
- Conditions
- IgA Nephropathy (IgAN), Renal and Urinary Disorders, Berger Disease
- Trial name
- ORIGIN EXTEND (NCT06674577)
- Testing
- Atacicept 150 mg
- Where
- United States
- Volunteers
- 750 people
- Sponsor
- Vera Therapeutics, Inc.
Immunoglobulin A Nephropathy, IgAN - IgA Nephropathy
First in Human Study to Assess Safety of VIS649 in Healthy Subjects
This is a phase 1, randomized, placebo-controlled, double-blind, single ascending dose study of IV VIS649 in healthy subjects. VIS649 is a monoclonal immunoglobulin G2 (IgG2) antibody targeting the B-cell growth factor APRILL.
- Conditions
- Immunoglobulin A Nephropathy, IgAN - IgA Nephropathy, IgA Nephropathy
- Trial name
- NCT03719443
- Testing
- VIS649
- Where
- United States
- Volunteers
- 51 people, healthy volunteers welcome
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
IGA Nephropathy
Open Label Study of Fostamatinib in the Treatment of IgA Nephropathy
Phase 2, multi-center, open label extension study to evaluate 2 dose regimens of fostamatinib in approximately 25 subjects. The study will consist of 11 visits over 15 months.
- Trial name
- NCT02433236
- Testing
- Fostamatinib Disodium tablet 100 mg, Fostamatinib Disodium tablet 150 mg
- Sponsor
- Rigel Pharmaceuticals
IgA Nephropathy
A Clinical Study of SCTC21C in Participants With Plasma Cell-driven Autoimmune Diseases
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of SCTC21C in subjects with plasma cell-driven autoimmune diseases
- Trial name
- NCT06774664
- Testing
- SCTC21C
- Where
- 20 sites in China
- Volunteers
- 99 people
- Sponsor
- Sinocelltech Ltd.
Autoimmune Diseases, Systemic Lupus Erthematosus
Anti-CD19/BCMA CAR-NK Cells in Patients With B Cell Mediated Autoimmune Disease
this is an investigator-initiated trial aimed at evaluating the efficacy and safety of anti-CD19/BCMA CAR-NK Cells in Patients With B cell mediated autoimmune disease.
- Conditions
- Autoimmune Diseases, Systemic Lupus Erthematosus, Multi-Drug Resistant Nephrotic Syndrome, IgAN - IgA Nephropathy
- Trial name
- NCT06792799
- Testing
- anti-CD19/BCMA CAR NK cells (KN5601)
- Where
- China
- Volunteers
- 36 people
- Sponsor
- The Children's Hospital of Zhejiang University School of Medicine
IgA Nephropathy, IgAN
Safety and Efficacy of AT-1501 in Patients With IgA Nephropathy (IgAN)
This is a phase 2a, multicenter, open-label study designed to evaluate the safety and efficacy of AT-1501 in patients with biopsy proven IgAN and at least 0.75 g/24 hours of protein in their urine at the time of screening.
- Trial name
- NCT05125068
- Testing
- AT-1501
- Where
- 26 sites in Australia, Croatia and 8 more
- Volunteers
- 24 people
- Sponsor
- Eledon Pharmaceuticals
IgA Nephropathy
IgA Nephropathy, Lymphocyte Homing and IgA Class Switch
IgA nephropathy (IgAN) is the most common primary glomerulonephritis in the world and it represents an important cause of end-stage kidney failure.
- Trial name
- NIDOCIGA (NCT01775527)
- Testing
- blood test
- Where
- France
- Volunteers
- 72 people, healthy volunteers welcome
- Sponsor
- University Hospital, Limoges
IgA Nephropathy
Clinical Study of CM338 in the Treatment of Immunoglobulin A Nephropathy
This study is a multicenter, randomized phase II clinical study to evaluate Efficacy and safety, while observing pharmacokinetic profiles, pharmacodynamic effects, and immunogenicity of CM338 in subjects with Immunoglobulin…
- Trial name
- NCT05775042
- Testing
- CM338
- Where
- China
- Volunteers
- 70 people
- Sponsor
- Keymed Biosciences Co.Ltd
IgA Nephropathy
An Observational Study of IgA Nephropathy: Pathological Variants and Clinical Data
The pathological variants of IgA nephropathy identified by the Oxford classification may be related to the clinical data at presentation and follow-up, including proteinuria and renal function.
- Trial name
- NCT01502579
- Where
- China
- Volunteers
- 603 people
- Sponsor
- Guangdong Provincial People's Hospital